Lead Product(s): AV-001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AV-001
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: US Department of Defense
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Funding August 18, 2020
Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).